PepGen

PEPG

Market cap $368M

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG). The investigation focuses on whether PepGen or certain of its executives violated federal securities laws.

PepGen said on Wednesday that the U.S. Food and Drug Administration has placed a partial clinical ​hold on its mid‑stage trial of a rare ‌muscle disease drug, sending its shares plunging over 25% in extended trading.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights. “2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing c.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory updates related to the FREEDOM2 trial. The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic d.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available.

The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio. On December 8, 2025, Mr. Vittiglio received a non-qualif.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance withi.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new composition of matter patent covering PGN-EDODM1, which leverages PepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform, including it.